<DOC>
	<DOCNO>NCT00884507</DOCNO>
	<brief_summary>This 4 arm study ass efficacy safety RO5313534 ( MEM3454 ) versus placebo add donepezil , patient mild moderate Alzheimer 's disease . Following screening period , patient randomize one 4 treatment ( placebo , RO5313534 1mg , 5mg 15mg po daily ) background therapy donepezil ( 5mg 10mg ) .The anticipated time study treatment 6 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study RO5313534 Add-on Donepezil Treatment Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>adult patient , &gt; /=50 year age ; probable Alzheimer 's disease ; MMSE score screening 1322 ; stable donepezil treatment give fix dose 5 10mg daily &gt; =4 month prior baseline ; require nursing home care , look caregiver/carer . dementia due condition Alzheimer 's disease ; significant neurological disorder ; untreated/nonstabilized major depressive disorder ; bipolar disorder , schizophrenia , serious psychiatric condition .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>